Sorry to hear the news. Am sure you have heard the news as of Sept 4 that Keytruda( MK-3475; pembolizumab) was approved by FDA as “first immunomodulator that acts as a programmed death (PD) inhibitor” for unresectable melanoma and others unresponsive to other drugs/surger. The PI is Antoni Ribas of UCLA Heme-Onc Dept. Do you know him? He says Keytruda can be used for other cancers than just Melanoma.
Merck will also combine it with Incyte drug, INCB24360 (an IDO inhibitor) . If results positive trials may be stopped.
There many other immumodulators in the works.
“Hang in there”.
Very best — Karlis
Best of health
Karlis C. Ullis, MD
Endocrinology, Sports & Preventive Medicine900 Wilshire Blvd.,Suite 425; Santa Monica, CA 90401310.452.1990 Fax: 310.452.5134Email: firstname.lastname@example.org http://ift.tt/1xGFCHF note e-mails may not be checked regularly and should not be used for urgent medical matters. Information contained in this e-mail & attached document(s) may contain confidential information that is intended only for the addressee(s). If you are not intended recipient, you are advised disclosure, copying, distribution, taking any action in response to the information is prohibited. If you have received this e-mail in error, immediately notify sender & delete it.
On Thu, Sep 11, 2014 at 7:50 PM, L. Stephen Coles M.D. Ph.D. wrote:
All: Although my CA-19-9 lab values gave us some cause for optimism,
my latest abdominal CT-Scan reveals that the metastatic tumor in the
right lobe of my liver has increased in volume by 50% from 3.5 cm
to 7.1 cm. As the tumor cells were laughing at the chemo poison,
the Taxotere was systematically destroying the rest of my body with
loss of all replicative stem-cell function from bone marrow to gut
and skeletal muscle satellite cells in particular, we determined to
the chemo treatment that would normally have started two days ago, now
that we have become aware that the tumor has become resistant to this
treatment. As a substitute treatment, I am seeking to enroll in a
clinical trial called ECLIPSE being run in part out of the UCLA Santa
Oncology Medical Division. It is an immune-stimulation trial based
a genetically-disabled Listeria vaccine. I am too tired to explain
now,.but I will attempt to keep you informed in another week. — Steve
L. Stephen Coles, M.D., Ph.D., Cofounder
Los Angeles Gerontology Research GroupE-mail: email@example.comE-mail: